This clinical trial tests whether increased activity throughout the day can improve the chronic pain and associated symptoms that breast cancer survivors may experience after surgery. Staying active is a key factor of one's physical, mental, and social health and well-being. Moving more could also reduce pain and associated stress, anxiety, or depression. Using a fitness tracker may help patients to move around more, whether or not they choose to exercise. Information gathered from this study may help researchers learn how the use of a Fitbit tracker with health coaching may improve physical activity and reduce pain in young, Hispanic breast cancer survivors.

开始日期2023-10-20

申办/合作机构

New Mexico Cancer Care Alliance

[+1]

NCT06207864

/ RecruitingN/AIIT

Participant Engagement - Cancer Genome Sequencing (PE-CGS) Research Center: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.

开始日期2022-03-22

申办/合作机构

New Mexico Cancer Care Alliance

[+1]

NCT05176743

/ CompletedN/AIIT

Food Insecurity in Oncology (FIOnc)

This trial will examine the feasibility and preliminary effectiveness of providing unconditional cash transfers to food insecure female breast and gynecologic cancer patients.
Approximately one-third of cancer survivors report food insecurity, characterized by limited access to adequate food for active, healthy living because of a lack of money and other resources. Unconditional cash transfers offer direct monetary assistance that can be used to meet immediate food or other financial needs and may positively impact health care resource utilization and health-related quality of life.

开始日期2021-08-30

申办/合作机构

New Mexico Cancer Care Alliance

[+2]

100 项与 New Mexico Cancer Care Alliance 相关的临床结果

登录后查看更多信息

0 项与 New Mexico Cancer Care Alliance 相关的专利（医药）

登录后查看更多信息

项与 New Mexico Cancer Care Alliance 相关的文献（医药）

2024-04-15·Cancer

A call to action to advance patient‐focused and decentralized clinical trials

Article

作者: Kim, Edward S ; Black, Lora J ; Merrill, Janette K ; Pollastro, Teri ; Symington, Banu E ; Waterhouse, David M ; Hamroun, Leila ; Boehmer, Leigh M ; Harvey, R Donald ; Brewer, Jamie R ; Hurley, Patricia A ; Holland, Nicole ; Levit, Laura A ; Tap, William D ; Thota, Ramya ; Miller, Therica M ; Prindiville, Sheila A ; Fleury, Mark E ; Bruinooge, Suanna S ; Kamboj, Jasmine ; Byatt, Leslie P ; Nowakowski, Grzegorz S ; Rizvi, Mujahid A

This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in clinical trials closer to home. Three key strategies are identified to address major barriers: confront challenges with the interpretation of US Food and Drug Administration Form 1572 requirements (Statement of Investigator); broaden acceptance of local laboratories and imaging centers; and invest in the creation of effective, sustainable partnerships between research centers and local providers.

2017-12-01·Journal of the American College of Radiology : JACR

Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners.

Article

作者: Lyss, Alan P ; Chang, George J ; Weaver, Kathryn E ; Sicks, JoRean D ; Stewart, Teresa L ; Sung, Lillian ; Carlos, Ruth C

PURPOSE:

Cancer care spans the spectrum from screening and diagnosis through therapy and into survivorship. Delivering appropriate care requires patient transitions across multiple specialties, such as primary care, radiology, and oncology. From the program's inception, the National Cancer Institute Community Oncology Research Program (NCORP) sites were tasked with conducting cancer care delivery research (CCDR) that evaluates structural, organizational, and social factors, including care transitions that determine patient outcomes. The aim of this study is to describe the capacity of the NCORP to conduct multidisciplinary CCDR that includes radiology and primary care practices.

METHODS:

The NCORP includes 34 community and 12 minority and underserved community sites. The Landscape Capacity Assessment was conducted in 2015 across these 46 sites, composed of the 401 components and subcomponents designated to conduct CCDR. Each respondent had the opportunity to designate an operational practice group, defined as a group of components and subcomponents with common care practices and resources. The primary outcomes were the proportion of adult oncology practice groups with affiliated radiology and primary care practices. The secondary outcomes were the proportion of those affiliated radiology and primary care groups that participate in research.

RESULTS:

Eighty-seven percent of components and subcomponents responded to at least some portion of the assessment, representing 230 practice groups. Analyzing the 201 adult oncology practice groups, 85% had affiliated radiologists, 69% of whom participate in research. Seventy-nine percent had affiliated primary care practitioners, 31% of whom participate in research. Institutional size, multidisciplinary group practice, and ownership by large regional or multistate health systems was associated with research participation by affiliated radiology and primary care groups. Research participation by these affiliated specialists was not significantly different between the community and the minority and underserved community sites.

CONCLUSIONS:

Research relationships exist between the majority of community oncology sites and affiliated radiology practices. Research relationships with affiliated primary care practices lagged. NCORP as a whole has the opportunity to encourage continued and expanded engagement where relationships exist. Where no relationship exists, the NCORP can encourage recruitment, particularly of primary care practices as partners.

2012-03-01·Annals of oncology : official journal of the European Society for Medical Oncology1区 · 医学

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen

1区 · 医学

Article

作者: Snyder, D ; Bocklage, T ; Schmit, B ; Muller, C Y ; Verschraegen, C F ; Quinn, R ; Movva, S ; Purdy, M ; Cerilli, L A ; Eberhardt, S ; Arias-Pulido, H ; Lee, S-J ; Rabinowitz, I

BACKGROUND:

To assess the response of patients with soft tissue sarcoma (STS) to the combination of docetaxel, bevacizumab, and gemcitabine. Vascular endothelial growth factor (VEGF)-A levels and expression of VEGF-A and VEGF receptors 1 and 2 were evaluated.

PATIENTS AND METHODS:

Thirty-eight chemotherapy-naive patients with STS were enrolled. A dose-finding study for gemcitabine from 1000, 1250, then 1500 mg/m² was done in nine patients (three cohorts), followed by an expansion cohort of 27 patients. Dose of docetaxel was 50 mg/m², bevacizumab was 5 mg/kg, and gemcitabine was 1500 mg/m², every 2 weeks. Serum VEGF-A was measured by enzyme-linked immunosorbent assay and tissue VEGF-A and its receptors by immunohistochemistry.

RESULTS:

The median follow-up was 36 months. The overall response rate observed was 31.4%, with 5 complete and 6 partial responses, and 18 stable diseases lasting for a median of 6 months. There was no significant hematologic toxicity. The adverse events with the highest grade were attributed to bevacizumab. There was no correlation of VEGF pathway biomarkers with outcome.

CONCLUSIONS:

The combination of gemcitabine, docetaxel, and bevacizumab is safe and effective in patients with STS. The most concerning adverse events were consequences of bevacizumab administration. The benefit of bevacizumab in this patient population remains unclear.

100 项与 New Mexico Cancer Care Alliance 相关的药物交易

登录后查看更多信息

100 项与 New Mexico Cancer Care Alliance 相关的转化医学

登录后查看更多信息